Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer

Starting soon

Conditions studied: Brain Tumor Adult, Brain Metastases From Solid Tumors, Brain Tumor, Primary, Brain Tumor

In brief

This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.

Key facts

Study ID

NCT07226466

Run by

University of California, San Francisco

People needed

40

Starts

2026-07-01

Expected to finish

2028-10-31

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• >= 18 years old
• Diagnosis of a primary brain tumor OR #3. Not both #2 and #3.
• Diagnosis of primary solid tumor and secondary involvement of the brain
• If the patient has brain metastases: fewer than 5 brain metastases (post-operative and definitive allowed), none > 1 cm in max diameter.
• Candidate for standard of care / usual care (SOC) focused brain radiotherapy.
• No prior brain radiotherapy, including whole brain radiotherapy.
• Eastern Cooperative Oncology Group (ECOG) functional score 0 or 1.
• Estimated life expectancy post-treatment of > 2 years.

You may not qualify if…

• Diagnosis of neurodegenerative disease (Alzheimer's disease, Parkinson's disease).
• Diagnosis of memory disorder pre-treatment.
• Leptomeningeal disease or disease involving either hippocampus.

Where it is running

• University of California, San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.